Literature DB >> 4611361

Prolonged survival of renal allografts in outbred rabbits treated with donor specific F(ab')2 alloantibody.

D E Sutherland, R J Howard, S Dombrovskis, J S Najarian.   

Abstract

Renal allograft survival was prolonged in rabbits, a species in which antibody mediated hyperacute rejection can occur, by administering large quantities of donor specific F(ab')(2) alloantibody. In 13 control animals, onset of uremia with histological evidence of rejection occurred at a mean of 6.0 days. Eight of eight rabbits actively immunized and seven of nine rabbits passively immunized with unmodified donor specific IgG alloantibody hyperacutely rejected an allografted kidney. Four rabbits treated with non-specific F(ab')(2) for one week acutely rejected an allografted kidney at a mean of 6.2 days. In 12 recipient rabbits receiving 100-500 mg of donor specific F(ab')(2) alloantibody for a mean of 8.5 days, onset of uremia was delayed to a mean of 14.5 days following transplantation. Recipients were selected so that the donor specific F(ab')(2) alloantibody employed had no activity against recipient antigens. This selection maximized the antigenic difference between the donor and recipient, and also assured us that the donor specific F(ab')(2) was directed against antigens present in the donor but absent in the recipient. Passive administration of donor specific F(ab')(2) allowed antibody mediated suppression of a specific immune response to occur without risk of hyperacute rejection. However, the onset of rejection could not be delayed indefinitely by this treatment. The experimental conditions employed and the difficulties encountered closely resemble those which will occur for clinical utilization of passive immunological enhancement.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4611361      PMCID: PMC1343810          DOI: 10.1097/00000658-197412000-00011

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  35 in total

1.  Studies on the control of antibody synthesis. Effect of antibody affinity upon its ability to suppress antibody formation.

Authors:  J G Walker; G W Siskind
Journal:  Immunology       Date:  1968-01       Impact factor: 7.397

2.  Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells.

Authors:  F Kissmeyer-Nielsen; S Olsen; V P Petersen; O Fjeldborg
Journal:  Lancet       Date:  1966-09-24       Impact factor: 79.321

3.  Humoral factors in canine renal allograft rejection.

Authors:  D S Clark; J E Foker; R A Good; R L Varco
Journal:  Lancet       Date:  1968-01-06       Impact factor: 79.321

4.  Immunologic enhancement of renal allografts in the rat.

Authors:  F P Stuart; T Saitoh; F W Fitch; B H Spargo
Journal:  Surgery       Date:  1968-07       Impact factor: 3.982

5.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

6.  Prolonged cancine renal allograft survival after pretreatment with solubilized antigen.

Authors:  R E Wilson; A Rippin; R K Dagher; P Kinneart; G J Busch
Journal:  Transplantation       Date:  1969-05       Impact factor: 4.939

7.  A simple micro cytotoxicity test.

Authors:  D B Amos; H Bashir; W Boyle; M MacQueen; A Tiilikainen
Journal:  Transplantation       Date:  1969-03       Impact factor: 4.939

8.  The immunosuppressive effect of passively administered antibody IgG fragments.

Authors:  J C Cerottini; P J McConahey; F J Dixon
Journal:  J Immunol       Date:  1969-04       Impact factor: 5.422

9.  Regulation of the immune response. I. Reduction in ability of specific antibody to inhibit long-lasting IgG immunological priming after removal of the Fc fragment.

Authors:  R Nicholas; S C Sinclair
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

10.  Estimation of the molecular weights of proteins by Sephadex gel-filtration.

Authors:  P Andrews
Journal:  Biochem J       Date:  1964-05       Impact factor: 3.766

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.